Filtered By:
Cancer: Oral Cancer
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 123 results found since Jan 2013.
Efficacy and safety of a dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study
CONCLUSIONS: The dexamethasone-based mouthwash safely reduced stomatitis incidence and severity in patients receiving chemotherapy for early breast cancer. Phase 3 clinical trials are warranted for validating our results.PMID:37689451 | DOI:10.1016/j.jebdp.2023.101896
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Sayaka Kuba Shigeto Maeda Kenichiro Shibata Sakiko Soutome Kosho Yamanouchi Megumi Matsumoto Aya Tanaka Michi Morita Toshiko Hatachi Ryota Otsubo Hiroshi Yano Yumiko Kawashita Shuntaro Sato Hideki Taniguchi Kengo Kanetaka Masahiro Umeda Takeshi Nagayasu S Source Type: research
Identification of an endoplasmic reticulum stress-related prognostic risk model with excellent prognostic and clinical value in oral squamous cell carcinoma
CONCLUSION: A prognostic model with high clinical application value was constructed. Immune cells, cellular stemness, and TMB may be involved in the progression of OSCC.PMID:37647077 | DOI:10.18632/aging.204983
Source: Aging - August 30, 2023 Category: Biomedical Science Authors: Mingyang Cheng Xin Fan Mu He Xianglin Dai Xiaoli Liu Jinming Hong Laiyu Zhang Lan Liao Source Type: research
Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3 β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model
Bioorg Chem. 2023 Jun 25;139:106700. doi: 10.1016/j.bioorg.2023.106700. Online ahead of print.ABSTRACTGaleterone, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Gal, 1) and VNPP433-3β, 3β-(1H-imidazole-1-yl-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (2) are potent molecular glue degrader modulators of AR/AR-V7 and Mnk1/2-eIF4E signaling pathways, and are promising Phase 3 and Phase 1 drug candidates, respectively. Because appropriate salts can be utilized to create new chemical entities with enhanced aqueous solubility, in vivo pharmacokinetics, and enhanced in vitro and in vivo efficacies, the monohydro...
Source: Bioorganic Chemistry - July 1, 2023 Category: Chemistry Authors: Retheesh S Thankan Elizabeth Thomas Puranik Purushottamachar David J Weber Vincent C O Njar Source Type: research
Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
J Clin Oncol. 2023 Jun 2:JCO2300723. doi: 10.1200/JCO.23.00723. Online ahead of print.ABSTRACTThe Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.For generation...
Source: Clinical Prostate Cancer - June 2, 2023 Category: Cancer & Oncology Authors: Jeremiah Wala Paul Nguyen Mark Pomerantz Source Type: research
Nanoencapsulation of Docetaxel Induces Concurrent Apoptosis and Necroptosis in Human Oral Cancer Cells (SCC-9) via TNF- α/RIP1/RIP3 Pathway
Indian J Clin Biochem. 2023 Jul;38(3):351-360. doi: 10.1007/s12291-022-01055-7. Epub 2022 Aug 9.ABSTRACTHuman oral squamous cell carcinoma is the sixth most frequent malignant cancer, with an unacceptably high death rate that affects people's health. Albeit, there are several clinical approaches for diagnosing and treating oral cancer they are still far from ideal. We previously synthesised and characterised the docetaxel nanoformulation (PLGA-Dtx) and discovered that docetaxel nanoencapsulation may suppress oral cancer cells. The goal of this study was to figure out the mechanism involved in the suppression of oral cancer...
Source: Clinical Biochemistry - May 26, 2023 Category: Biochemistry Authors: Parul Gupta Arpita Singh Ajay Kumar Verma Surya Kant Anuj Kumar Pandey Anupam Mishra Puneet Khare Ved Prakash Source Type: research
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer
CONCLUSION: Treatment with relugolix was associated with similar efficacy and safety profiles with and without concomitant enzalutamide or docetaxel. Standard-of-care use of relugolix in combination with these agents is supported by these data.PMID:37062659 | DOI:10.1016/j.clgc.2023.03.009
Source: Clinical Prostate Cancer - April 16, 2023 Category: Cancer & Oncology Authors: Daniel J George Fred Saad Michael S Cookson Daniel R Saltzstein Ronald Tutrone Alberto Bossi Bruce Brown Bryan Selby Sophia Lu David Buckley Bertrand Tombal Neal D Shore Source Type: research
Engineered Microencapsulated Lactoferrin Nanoconjugates for Oral Targeted Treatment of Colon Cancer
This study provides the proof of concept for using NIMDs to enhance the effect of protein NPs in CRC treatment.PMID:37039769 | DOI:10.1021/acs.biomac.3c00037
Source: Biomacromolecules - April 11, 2023 Category: Biochemistry Authors: Yomna M Elmorshedy Mohamed Teleb Marwa A Sallam Kadria A Elkhodairy Mohammed Bahey-El-Din Doaa A Ghareeb Shaymaa A Abdulmalek Shimaa A H Abdel Monaim Adnan A Bekhit Ahmed O Elzoghby Fernando Albericio Sherine N Khattab Source Type: research
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT02446405, ANZCTR, ACTRN12614000110684, and EudraCT, 2014-003190-42.FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63-74). This analysis was triggered on Jan 19, 2022, and an updated survival status identified a total of 476 (42%) deaths. After a median follow-up of 68 months (IQR 67-69), the median overall survival was not reached (hazard ratio 0·70 [95% CI 0·58-0·84]; p<0·0001), with 5-year overall ...
Source: Cancer Control - March 29, 2023 Category: Cancer & Oncology Authors: Christopher J Sweeney Andrew J Martin Martin R Stockler Stephen Begbie Leanna Cheung Kim N Chi Simon Chowdhury Mark Frydenberg Lisa G Horvath Anthony M Joshua Nicola J Lawrence Gavin Marx John McCaffrey Ray McDermott Margaret McJannett Scott A North Franc Source Type: research
Clinical significance and integrative analysis of the cuproptosis-associated genes in head and neck squamous cell carcinoma
Aging (Albany NY). 2023 Mar 20;15. doi: 10.18632/aging.204579. Online ahead of print.ABSTRACTHead and neck squamous cell carcinoma (HNSC) is a kind of malignant tumor originating from the oropharynx, larynx, nasopharynx and oral cavity. The incidence of HNSC is increasing and it is the sixth malignant tumor in the world at present. "Cuprotosis" is a novel cuper-dependent cell death mode that is closely related to mitochondrial respiration. Tumorigenesis is closely related to the dysregulation of cell death. However, the relationship between cuprotosis and HNSC remains unclear. Here, we investigated the association between ...
Source: Aging - March 22, 2023 Category: Biomedical Science Authors: Qiu Peng Xianjie Jiang Shiming Tan Xuemeng Xu Longzheng Xia Nayiyuan Wu Jinguan Lin Linda Oyang Yanyan Tang Mingjing Peng Min Su Xia Luo Yaqian Han Qianjin Liao Yujuan Zhou Source Type: research
